What question did this study set out to answer?

January 23, 2026

P1290 Prevalence and Risk Factors for Extraintestinal Manifestations in Moroccan Inflammatory Bowel Disease Patients

Key Points

To assess the prevalence and identify risk factors for extraintestinal manifestations in Moroccan patients with inflammatory bowel disease.
Conducted a cross-sectional study from 2016 to 2023
Included 715 IBD patients diagnosed at a tertiary care center
Defined extraintestinal manifestations based on specific medical criteria
Utilized multivariable logistic regression for analysis
Overall prevalence of extraintestinal manifestations was 14.3%
Prevalence in Crohn's disease was 16.1%, in ulcerative colitis was 12.6%, and in IBD-unclassified was 9.5%
Patients with Crohn's disease had a higher risk of EIMs compared to those with ulcerative colitis (OR 1.99)
Risk of EIMs increased with age (OR 1.026 per year)

Abstract

Abstract Background Extraintestinal manifestations (EIMs) significantly affect prognosis and quality of life in patients with inflammatory bowel disease (IBD). There are no large-scale data from Morocco describing their prevalence and associated risk factors. Methods We conducted a cross-sectional study between 2016 and 2023 at a tertiary care center in eastern Morocco, including 715 consecutive patients diagnosed with IBD: Crohn’s disease (CD, n = 415), ulcerative colitis (UC, n = 231), and IBD-unclassified (IBDU, n = 63). EIMs were defined as the presence of ≥1 of the following: • Musculoskeletal (spondyloarthritis, arthritis, psoriatic arthritis) • Ocular (uveitis, episcleritis) • Skin manifestations (erythema nodosum, pyoderma gangrenosum) • Hepatobiliary (primary sclerosing cholangitis, autoimmune hepatitis) Multivariable logistic regression was used to identify independent associations with age, sex, diagnosis, and disease duration. Results Among 715 IBD patients, the overall prevalence of EIMs was 14.3%: CD 16.1%, UC 12.6%, IBDU 9.5%. In multivariable analysis, risk of EIMs was higher in Crohn’s disease vs UC (OR 1.99, 95% CI 1.18–3.36, p = 0.010) and increased with age (OR 1.026 per year, 95% CI 1.010–1.042, p = 0.001); female sex (OR 1.13, 95% CI 0.73–1.77, p = 0.58) and disease duration (OR 0.97, 95% CI 0.93–1.01, p = 0.086) were not significant. Distribution of EIMs: musculoskeletal 6.7%, ocular 2.0%, skin 1.3%, hepatobiliary 4.9% Conclusion In this large Moroccan IBD cohort, approximately 1 in 7 patients presented with an EIM, with higher risk in Crohn’s disease and in older individuals. Disease duration showed a slight, non-significant inverse trend with EIM occurrence. These findings highlight the importance of systematic screening for EIMs, particularly in Crohn’s disease. Conflict of interest: Dr. Naciri, Fatine: No conflict of interest El Ouahabi, Dikra: No conflict of interest Elmqaddem, Ouiam: No conflict of interest Koulali, Hajar: No conflict of interest Zazour, Abdelkrim: No conflict of interest Ismaili, Zahi: No conflict of interest Kharrasse, Ghizlane: No conflict of interest

Mark Helpful

Bookmark

Relay